Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial
- 28 January 2022
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 247, 33-41
Abstract
No abstract availableKeywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (33IC30_166872)
This publication has 24 references indexed in Scilit:
- Timing of Cardiovascular MR Imaging after Acute Myocardial Infarction: Effect on Estimates of Infarct Characteristics and Prediction of Late Ventricular RemodelingRadiology, 2011
- Everolimus in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2010
- Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2010
- Microvascular ObstructionJACC, 2010
- Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of RestenosisJACC: Cardiovascular Interventions, 2009
- Impact of Heterogeneity of Human Peripheral Blood Monocyte Subsets on Myocardial Salvage in Patients With Primary Acute Myocardial InfarctionJACC, 2009
- Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) studyEuroIntervention, 2009
- Immunoregulatory functions of mTOR inhibitionNature Reviews Immunology, 2009
- Oral Rapamycin After Coronary Bare-Metal Stent Implantation to Prevent RestenosisJACC, 2006
- Randomized, Double-Blind, Placebo-Controlled Trial of Oral Sirolimus for Restenosis Prevention in Patients With In-Stent RestenosisCirculation, 2004